RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction

Joaquim CristinoNovartis Pharmaceuticals, Basel, Switzerland;

Immanuel TangNovartis Pharmaceuticals, Singapore;

Caroline NgNovartis Pharmaceuticals, Singapore;

Jonathan TanNovartis Pharmaceuticals, Singapore;

David TruemanSourceHEOR Consultancy, London, UK;

Declan LeeNovartis Pharmaceuticals, Dublin, IrelandCorrespondence[email protected]

Click to increase image sizeClick to decrease image size

View responses to this article:

Reply: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction

Transparency

Declaration of funding

There is no funding to report.

Declaration of financial/other relationships

JC, IT, CN, JT, and DL are employees of Novartis. DT is a director at SourceHEOR, which has provided HEOR consultancy to Novartis.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction

Declaration of funding

Declaration of financial/other relationships

Information for

Open access

Opportunities

Help and information

RE: Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction

Transparency

Declaration of funding

Declaration of financial/other relationships

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature